Kineta, Inc. (KA)
| Market Cap | 26.28M |
| Revenue (ttm) | 4.84M |
| Net Income (ttm) | -32.00M |
| Shares Out | 8.32M |
| EPS (ttm) | -21.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $10.01 (316.77%) |
| Ex-Dividend Date | Dec 19, 2022 |
| Volume | 42,590 |
| Open | 3.99 |
| Previous Close | 3.91 |
| Day's Range | 3.12 - 4.01 |
| 52-Week Range | 2.87 - 15.54 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 10, 2023 |
About KA
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington. [Read more]
Financial Performance
In 2021, Kineta's revenue was $8.04 million, an increase of 16.65% compared to the previous year's $6.90 million. Losses were -$39.50 million, -22.22% less than in 2020.
Financial StatementsNews
Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune...
Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference
SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune...
Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target
SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance,...
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board
SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance,...
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
Yumanity Therapeutics (NASDAQ: YMTX) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a special dividend. According to a press release from the company...
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
Special dividend estimated to be in range of $1.34 to $1.43 per share
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results for th...
Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, di...
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development ...
YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Yumanity Therapeutics, Inc. (NasdaqCM...
Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?
Yumanity Therapeutics (YMTX) stock is rocketing higher on Monday after announcing two definitive agreements. including a merger.
Yumanity Therapeutics Shares Trading Higher Today - Read Here Why
Yumanity Therapeutics Inc (NASDAQ: YMTX) has agreed to sell its lead clinical-stage product candidate, YTX-7739, and discovery-stage neuroscience candidates to Janssen Pharmaceutica NV, a unit of John...
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in ...
Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates
Yumanity (YMTX) delivered earnings and revenue surprises of -21.57% and 31.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying th...
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring
BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying the...
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying the...
Yumanity Shares Fall On FDA Hold On Multidose Trials In Parkinson's Disease
The FDA has placed a partial clinical hold on Yumanity Therapeutics Inc's (NASDAQ: YMTX) multidose clinical trials of YTX-7739, currently being developed for Parkinson's disease. The FDA has not halt...
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying the...
Yumanity's Approach to Neurodegenerative Diseases Validated by Two External Collaborations
Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying the...
Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying the...